Catalyst Event
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
6/2/2026, 12:00:00 AM
Kelun-Biotech announced positive first-in-human study results for its novel B7-H3 ADC drug, SKB500, at the 2026 ASCO annual meeting on June 2, 2026. The data showed broad-spectrum antitumor activity across multiple solid tumors, with notable efficacy in small cell lung cancer (SCLC).
Korean Translation
2026년 6월 2일 ASCO 연례회의에서 신규 B7-H3 ADC 약물 SKB500의 첫 인체 대상 임상 연구에서 긍정적인 결과를 발표함. 데이터는 다양한 고형암에 걸쳐 광범위한 항종양 활성을 보였으며, 특히 소세포폐암(SCLC)에서 주목할 만한 효능을 나타냄.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Aimed Bio Inc (0009K0) · Other
Stock price dropped approximately 18% on June 4, 2026, reportedly due to the expiration of a post-IPO lock-up period, which led to a significant volume of shares being sold by institutional investors.
6/4/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
6/4/2026, 12:00:00 AM